{"id":7380,"date":"2016-01-29T06:42:59","date_gmt":"2016-01-29T06:42:59","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/"},"modified":"2016-01-29T06:42:59","modified_gmt":"2016-01-29T06:42:59","slug":"nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/","title":{"rendered":"Nicox accorde \u00e0 Ora, Inc. la licence de son m\u00e9dicament sans prescription AC-120"},"content":{"rendered":"<ul>\n<li>\n<h2><strong>Valorisation par Nicox d\u2019un produit OTC (m\u00e9dicament sans prescription) issu de l&rsquo;acquisition d&rsquo;Aciex, tout en concentrant ses ressources sur son portefeuille de produits avec prescription ciblant des pathologies ophtalmiques majeures <\/strong><\/h2>\n<\/li>\n<li>\n<h2><strong>Paiement d\u2019\u00e9tape \u00e0 recevoir par Nicox \u00e0 l\u2019approbation et pourcentage sur les revenus futurs <br \/> d&rsquo;AC-120<\/strong><\/h2>\n<\/li>\n<li>\n<h2><strong>Financement par Ora de l&rsquo;ensemble des activit\u00e9s de d\u00e9veloppement<\/strong><\/h2>\n<\/li>\n<li>\n<h2><strong>Phase\u00a02\/3 \u00e0 venir dans le gonflement palp\u00e9bral matinal (syndrome des \u00ab\u00a0yeux gonfl\u00e9s\u00a0\u00bb)<\/strong><\/h2>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>Sophia Antipolis, France et Andover, Massachusetts (\u00c9tats-Unis)<\/p>\n<p><strong>Nicox\u00a0S.A. <\/strong>(Euronext Paris\u00a0: FR0013018124, COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, et <strong>Ora,\u00a0Inc.<\/strong>, leader mondial de la recherche clinique et du d\u00e9veloppement de produits ophtalmiques, annoncent aujourd&rsquo;hui la signature d\u2019un accord de licence entre Nicox Ophthalmics, Inc., la filiale am\u00e9ricaine de Nicox, et Ora. Cet accord accorde \u00e0 Ora l&rsquo;exclusivit\u00e9 mondiale des droits sur le d\u00e9veloppement et la commercialisation de l&rsquo;AC-120 de Nicox, un candidat-m\u00e9dicament innovant contre le gonflement palp\u00e9bral matinal.<\/p>\n<p>Selon les termes du contrat de licence exclusif annonc\u00e9 ce jour, Ora prendra en charge toutes les activit\u00e9s de d\u00e9veloppement et financera ce programme au travers de sa branche d\u2019investissement. Ora entend ainsi poursuivre le d\u00e9veloppement clinique de l&rsquo;AC-120 avant d&rsquo;octroyer une sous-licence de commercialisation \u00e0 un tiers. En cas d\u2019approbation de l&rsquo;AC\u2011120 par la <em>Food and Drug Administration<\/em> (FDA) am\u00e9ricaine, Nicox recevrait d\u2019Ora un paiement d\u2019\u00e9tape de 10\u00a0millions\u00a0de dollars. De plus, Nicox recevrait un pourcentage sur l\u2019ensemble des revenus que pourrait percevoir Ora dans le cadre d\u2019un accord de sous-licence.<\/p>\n<blockquote>\n<p><strong>Gavin Spencer, <em>Executive Vice-President<\/em> <em>Corporate Development<\/em> de Nicox<\/strong>, d\u00e9clare\u00a0: \u00ab\u00a0<em>L&rsquo;AC<\/em><em>\u2011<\/em><em>120 est un m\u00e9dicament ayant vocation \u00e0 \u00eatre propos\u00e9 en vente libre, sans prescription m\u00e9dicale. D\u00e9velopp\u00e9 par Aciex\u00a0Therapeutics avant son acquisition par Nicox, l\u2019AC-120 pr\u00e9sente un fort potentiel dans le traitement d\u2019un probl\u00e8me fr\u00e9quent, le gonflement matinal des paupi\u00e8res. La d\u00e9cision d\u2019en c\u00e9der la licence \u00e0 Ora s\u2019inscrit dans notre strat\u00e9gie visant \u00e0 d\u00e9velopper des m\u00e9dicaments avec prescription ciblant des pathologies ophtalmiques majeures. Ora est un partenaire id\u00e9al pour poursuivre le d\u00e9veloppement\u00a0de ce m\u00e9dicament compte tenu de son exp\u00e9rience et de ses capacit\u00e9s \u00e0 d\u00e9finir la strat\u00e9gie de d\u00e9veloppement clinique et r\u00e9glementaire ainsi qu\u2019\u00e0 identifier les meilleurs partenaires commerciaux, gr\u00e2ce notamment \u00e0 son vaste r\u00e9seau dans l\u2019industrie pharmaceutique. Nous sommes ravis qu\u2019Ora apporte ses ressources pour faire avancer ce projet tandis que nous consacrerons les n\u00f4tres \u00e0 notre portefeuille propri\u00e9taire de m\u00e9dicaments avec prescription, conform\u00e9ment \u00e0 notre strat\u00e9gie pr\u00e9sent\u00e9e au mois de d\u00e9cembre 2015 pour nos activit\u00e9s commerciales en Europe.<\/em>\u00a0\u00bb<\/p>\n<p><strong>Stuart B.\u00a0Abelson, Pr\u00e9sident Directeur G\u00e9n\u00e9ral d&rsquo;Ora,\u00a0Inc.<\/strong>, ajoute\u00a0: \u00ab\u00a0<em>La congestion palp\u00e9brale matinale est un probl\u00e8me r\u00e9pandu, jusqu&rsquo;ici sans r\u00e9ponse sp\u00e9cifique, qui constitue une opportunit\u00e9 significative sur le march\u00e9 des m\u00e9dicaments vendus sans ordonnance. Nos pr\u00e9c\u00e9dentes exp\u00e9riences positives dans le d\u00e9veloppement de l\u2019AC-120 et d&rsquo;autres m\u00e9dicaments de Nicox\/Aciex nous confortent dans le futur d\u00e9veloppement de l\u2019AC-120 et son potentiel \u00e0 long terme. Nous sommes impatients de lancer l\u2019\u00e9tude de phase\u00a02\/3 pour ce m\u00e9dicament.<\/em>\u00a0\u00bb<\/p>\n<\/blockquote>\n<p>L&rsquo;AC-120 est un collyre ciblant la congestion des paupi\u00e8res au petit matin (\u00e9galement appel\u00e9e \u00ab\u00a0syndrome des yeux gonfl\u00e9s\u00a0\u00bb), une condition dont la fr\u00e9quence augmente avec l&rsquo;\u00e2ge, en particulier chez les femmes, et qui peut avoir des causes vari\u00e9es. Dans un programme clinique de phase\u00a02 men\u00e9 par Aciex et Ora, le traitement par l\u2019AC\u2011120 a d\u00e9j\u00e0 r\u00e9v\u00e9l\u00e9 une r\u00e9duction statistiquement significative du gonflement matinal palp\u00e9bral. L\u2019AC-120 a \u00e9galement \u00e9t\u00e9 bien tol\u00e9r\u00e9, sans effet ind\u00e9sirable signal\u00e9.<\/p>\n<p>Nicox a acquis l&rsquo;AC\u2011120 en octobre 2014 dans le cadre de l\u2019acquisition d\u2019Aciex Therapeutics,\u00a0Inc., laquelle a ensuite \u00e9t\u00e9 renomm\u00e9e Nicox Ophthalmics,\u00a0Inc. Selon les termes de l&rsquo;acquisition d&rsquo;Aciex, Nicox pourrait verser jusqu&rsquo;\u00e0 10\u00a0millions\u00a0de dollars en actions Nicox aux anciens actionnaires d&rsquo;Aciex si l&rsquo;AC-120 venait \u00e0 \u00eatre approuv\u00e9 par la FDA (cf. communiqu\u00e9 de presse de Nicox du 2 juillet 2014).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Valorisation par Nicox d\u2019un produit OTC (m\u00e9dicament sans prescription) issu de l&rsquo;acquisition d&rsquo;Aciex, tout en concentrant ses ressources sur son portefeuille de produits avec prescription ciblant des pathologies ophtalmiques majeures Paiement d\u2019\u00e9tape \u00e0 recevoir par Nicox \u00e0 l\u2019approbation et pourcentage sur les revenus futurs d&rsquo;AC-120 Financement par Ora de l&rsquo;ensemble des activit\u00e9s de d\u00e9veloppement Phase\u00a02\/3 [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7380","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox accorde \u00e0 Ora, Inc. la licence de son m\u00e9dicament sans prescription AC-120 - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox accorde \u00e0 Ora, Inc. la licence de son m\u00e9dicament sans prescription AC-120 - Nicox\" \/>\n<meta property=\"og:description\" content=\"Valorisation par Nicox d\u2019un produit OTC (m\u00e9dicament sans prescription) issu de l&rsquo;acquisition d&rsquo;Aciex, tout en concentrant ses ressources sur son portefeuille de produits avec prescription ciblant des pathologies ophtalmiques majeures Paiement d\u2019\u00e9tape \u00e0 recevoir par Nicox \u00e0 l\u2019approbation et pourcentage sur les revenus futurs d&rsquo;AC-120 Financement par Ora de l&rsquo;ensemble des activit\u00e9s de d\u00e9veloppement Phase\u00a02\/3 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2016-01-29T06:42:59+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox accorde \u00e0 Ora, Inc. la licence de son m\u00e9dicament sans prescription AC-120\",\"datePublished\":\"2016-01-29T06:42:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\\\/\"},\"wordCount\":728,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\\\/\",\"name\":\"Nicox accorde \u00e0 Ora, Inc. la licence de son m\u00e9dicament sans prescription AC-120 - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2016-01-29T06:42:59+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox accorde \u00e0 Ora, Inc. la licence de son m\u00e9dicament sans prescription AC-120 - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox accorde \u00e0 Ora, Inc. la licence de son m\u00e9dicament sans prescription AC-120 - Nicox","og_description":"Valorisation par Nicox d\u2019un produit OTC (m\u00e9dicament sans prescription) issu de l&rsquo;acquisition d&rsquo;Aciex, tout en concentrant ses ressources sur son portefeuille de produits avec prescription ciblant des pathologies ophtalmiques majeures Paiement d\u2019\u00e9tape \u00e0 recevoir par Nicox \u00e0 l\u2019approbation et pourcentage sur les revenus futurs d&rsquo;AC-120 Financement par Ora de l&rsquo;ensemble des activit\u00e9s de d\u00e9veloppement Phase\u00a02\/3 [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/","og_site_name":"Nicox","article_published_time":"2016-01-29T06:42:59+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/"},"author":{"name":"","@id":""},"headline":"Nicox accorde \u00e0 Ora, Inc. la licence de son m\u00e9dicament sans prescription AC-120","datePublished":"2016-01-29T06:42:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/"},"wordCount":728,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/","url":"https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/","name":"Nicox accorde \u00e0 Ora, Inc. la licence de son m\u00e9dicament sans prescription AC-120 - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2016-01-29T06:42:59+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-accorde-a-ora-inc-la-licence-de-son-medicament-sans-prescription-ac-120-2\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7380"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7380\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}